ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Clinical value of LncRNA PAX8-AS1 as a biomarker for sepsis diagnosis and prognosis and its regulatory mechanism via the miR-34a-5p/HDAC1 axis.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this research is to evaluate the diagnostic and prognostic significance of lncRNA PAX8-AS1 in sepsis, and explore its function in regulating the inflammatory response at the molecular level.
methodsThis study included 112 sepsis patients and 100 healthy controls. The levels of PAX8-AS1, miR-34a-5p, and target mRNA were quantified using qRT-PCR. Kaplan-Meier analysis was performed to assess 28-day survival. ROC curves were used to evaluate diagnostic efficacy. ELISA measured inflammatory cytokine concentrations. The targeting relationship between PAX8-AS1 and miR-34a-5p, along with the regulatory effect of miR-34a-5p on HDAC1, was confirmed through bioinformatics prediction, dual luciferase reporter assays, and RNA pull-down experiments.
resultsPAX8-AS1 expression was significantly higher in sepsis patients, and its expression level positively correlated with the severity of sepsis. PAX8-AS1 demonstrated high diagnostic efficacy for sepsis with an AUC of 0.913. Furthermore, the lower 28-day cumulative survival was observed in patients with high PAX8-AS1 expression relative to their low-expression counterparts. In THP-1 cells, silencing PAX8-AS1 suppressed the inflammatory response triggered by LPS. Mechanistically, PAX8-AS1 sponges miR-34a-5p to exacerbate the inflammatory response. HDAC1 is a direct target of miR-34a-5p.
conclusionsPAX8-AS1 is highly expressed in sepsis patients and demonstrates diagnostic and prognostic value. By binding to miR-34a-5p to upregulate HDAC1 expression, it promotes inflammatory response.
Indexed as
Identifiers
42154028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.